

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 January 2025 (02.01.2025)



(10) International Publication Number
WO 2025/006962 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/553 (2006.01)
C07D 519/00 (2006.01) A61K 31/519 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/036126

(22) International Filing Date:

28 June 2024 (28.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,455	30 June 2023 (30.06.2023)	US
63/588,239	05 October 2023 (05.10.2023)	US
63/551,905	09 February 2024 (09.02.2024)	US
63/655,965	04 June 2024 (04.06.2024)	US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **FINK, Brian Edward**; c/o Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **SHIRUDE, Pravin S.**;
c/o Bristol-Myers Squibb India Private Limited, The India
Bulls Finance Centre, 6th Floor, Tower 1, Mumbai 400013
(IN). **CHATTOPADHYAY, Amit Kumar**; Syngene Intl.
Ltd. Biocon Park, Plot Nos. 2 & 3, Bommasandra Ind. Area
IV Phase, Jigani Link Rd., Bangalore 560099 (IN). **NAN-
DA, Laxmi Narayan**; Syngene Intl. Ltd. Biocon Park, Plot
Nos. 2 & 3, Bommasandra Ind. Area IV Phase, Jigani Link
Rd., Bangalore 560099 (IN). **BALIGAR, Vishweshwara-
iah**; Syngene Intl. Ltd. Biocon Park, Plot Nos. 2 & 3, Bom-
masandra Ind. Area IV Phase, Jigani Link Rd., Bangalore
560099 (IN). **SESHADRI, Balaji**; Syngene Intl. Ltd. Bio-
con Park, Plot Nos. 2 & 3, Bommasandra Ind. Area IV
Phase, Jigani Link Rd., Bangalore 560099 (IN). **DHAR,
T.G. Murali**; c/o Bristol-Myers Squibb Company, Route
206 and Province Line Road, Princeton, New Jersey 08543
(US). **SUN, Li-Qiang**; c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, New Jersey
08543 (US). **ZHENG, Zhizhen Barbara**; c/o Bristol-My-
ers Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **PANDA, Manoranjan**;
Bristol-Myers Squibb India Private Limited, The India Bulls
Finance Centre, 6th Floor, Tower 1, Mumbai 400013 (IN).
PALKOWITZ, Maximilian David; 91 Sidney Street #708,
Cambridge, Massachusetts 02139 (US). **LAKKARAJU,
Sirish Kaushik**; c/o Bristol-Myers Squibb Company, Rt.
206 & Province Line Road, Princeton, New Jersey 08543
(US). **BANERJEE, Moloy**; Syngene Intl. Ltd. Biocon Park,

Plot Nos. 2 & 3, Bommasandra Ind. Area IV Phase, Jigani
Link Rd., Bangalore 560099 (IN).

(74) Agent: **COVERT, John M.** et al.; STERNE, KESSLER,
GOLDSTEIN & FOX P.L.L.C., 1101 K Street NW, 10th
Floor, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: KRAS INHIBITORS

(57) Abstract: The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.



WO 2025/006962 A1